- Home
- LIVN vs PRCT Comparison
LIVN vs PRCT Comparison
Compare LIVN & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIVN
- PRCT
- Stock Information
- Founded
- LIVN 1987
- PRCT 2009
- Country
- LIVN United Kingdom
- PRCT United States
- Employees
- LIVN N/A
- PRCT N/A
- Industry
- LIVN Biotechnology: Electromedical & Electrotherapeutic Apparatus
- PRCT Medical Specialities
- Sector
- LIVN Health Care
- PRCT Health Care
- Exchange
- LIVN Nasdaq
- PRCT Nasdaq
- Market Cap
- LIVN 2.1B
- PRCT 2.1B
- IPO Year
- LIVN 1993
- PRCT 2021
- Fundamental
- Price
- LIVN $54.53
- PRCT $37.28
- Analyst Decision
- LIVN Strong Buy
- PRCT Buy
- Analyst Count
- LIVN 7
- PRCT 8
- Target Price
- LIVN $59.71
- PRCT $70.00
- AVG Volume (30 Days)
- LIVN 583.7K
- PRCT 962.8K
- Earning Date
- LIVN 10-29-2025
- PRCT 10-27-2025
- Dividend Yield
- LIVN N/A
- PRCT N/A
- EPS Growth
- LIVN N/A
- PRCT N/A
- EPS
- LIVN N/A
- PRCT N/A
- Revenue
- LIVN $1,309,329,000.00
- PRCT $274,950,000.00
- Revenue This Year
- LIVN $11.29
- PRCT $48.38
- Revenue Next Year
- LIVN $6.59
- PRCT $30.87
- P/E Ratio
- LIVN N/A
- PRCT N/A
- Revenue Growth
- LIVN 8.23
- PRCT 55.71
- 52 Week Low
- LIVN $32.48
- PRCT $36.90
- 52 Week High
- LIVN $58.91
- PRCT $103.81
- Technical
- Relative Strength Index (RSI)
- LIVN 50.60
- PRCT 39.66
- Support Level
- LIVN $56.42
- PRCT $36.90
- Resistance Level
- LIVN $57.53
- PRCT $39.40
- Average True Range (ATR)
- LIVN 1.35
- PRCT 1.88
- MACD
- LIVN -0.70
- PRCT 0.37
- Stochastic Oscillator
- LIVN 10.25
- PRCT 6.87
About LIVN LivaNova PLC
UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.